Skip to main content

Arvinas

Arvinas Inc is an American clinical-stage biopharmaceutical company focused on targeted protein degradation therapeutics. The company utilizes its proprietary PROTAC protein degradation platform to design therapies that harness the body's natural protein disposal system to selectively degrade disease-causing proteins. Revenue is primarily generated through research collaboration agreements, milestone payments, and license options with global biopharmaceutical companies. Core end markets serve oncology and neuroscience patient populations within global healthcare systems. Arvinas occupies a pioneering market position as the originator of PROTAC targeted protein degradation therapies in clinical development. The company is headquartered in New Haven, Connecticut, and its common stock trades on the Nasdaq Global Select Market.

5 of the funds FundTelligence covers report a position in Arvinas.

Legal name
Arvinas Inc
Sector
Health Care
Country
United States
Funds holding it
5

Funds holding Arvinas

Loading...